Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Memphasys Ltd ( (AU:MEM) ).
Memphasys Limited has secured A$1.275 million through a strategic placement to advance the commercialisation of its Felix™ and RoXsta™ systems. The funds will support licensing, joint ventures, and distribution agreements, particularly following successful clinical trial results for the Felix™ System, which demonstrated superior performance to existing sperm preparation methods. The RoXsta™ System is gaining traction in veterinary applications, showing potential for livestock reproductive health and early mastitis detection in dairy cattle.
More about Memphasys Ltd
Memphasys Limited is an Australian reproductive biotechnology company focused on developing advanced technologies for human and animal reproductive health. Their primary products include the Felix™ System, designed for assisted reproductive technology in humans, and the RoXsta™ System, which assesses oxidative stress in livestock, with applications in reproductive and animal health.
Average Trading Volume: 52,211,380
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$12.4M
For an in-depth examination of MEM stock, go to TipRanks’ Stock Analysis page.